Avelumab and Merkel Cell Carcinoma: Examining Causation and Risk
From General Health Science to Targeted Risk Inquiry
General health and science communication has long served as a foundation for public understanding of disease prevention and treatment. In this legacy context, audiences are familiar with broad concepts such as immune system function, cancer biology, and the role of therapeutic interventions in managing illness. This foundational knowledge provides a necessary backdrop for examining more specific, emerging concerns in occupational and environmental health. As we shift focus from general health education to a more targeted inquiry, a critical question arises regarding the relationship between pharmaceutical exposure and disease risk. Specifically, the therapeutic agent Avelumab, an immune checkpoint inhibitor, has been investigated in connection with Merkel cell carcinoma. While Avelumab is primarily used as a treatment for this rare skin cancer, the question of causation—whether exposure to the drug itself may be linked to the development or progression of the disease—represents a distinct and important occupational health consideration. This pivot from general health context to a focused exposure concern requires careful examination of the circumstances under which individuals might encounter Avelumab, particularly in workplace settings such as healthcare facilities or pharmaceutical manufacturing. The transition from broad health literacy to this specific risk assessment underscores the need for rigorous evaluation of exposure pathways, without presuming mechanistic explanations. By grounding this inquiry in established health communication principles, we can responsibly explore the potential implications of Avelumab exposure in occupational contexts.
Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma
Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). The clinical presentation of MCC typically involves a rapidly growing, painless, firm skin nodule, often on sun-exposed areas, and diagnosis is confirmed by histopathology and immunohistochemistry showing neuroendocrine markers. MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Adverse Effects and the Question of Causation
Regarding adverse effects, avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates the potential for avelumab to trigger or exacerbate autoimmune or inflammatory conditions. The mechanistic pathway linking avelumab to MCC is not one of causation in the sense of the drug causing the disease. Rather, avelumab is a treatment for MCC. The evidence indicates that avelumab is used to treat MCC, not to cause it. The query "Avelumab linked to Merkel cell carcinoma" may reflect a misunderstanding, as the drug is indicated for this cancer. However, there is a relevant clinical scenario: avelumab-refractory MCC. In patients whose disease progresses on avelumab, alternative therapies are needed. Studies have investigated the activity of ipilimumab plus nivolumab in avelumab-refractory MCC. In a multicenter study of the prospective skin cancer registry ADOREG, and in a retrospective study at three German sites, patients with metastatic MCC refractory to avelumab were treated with combined ipilimumab and nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/). In one report, three out of five patients responded to combined ipilimumab and nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). These findings highlight that avelumab-refractory disease is a recognized clinical entity, and that subsequent immune checkpoint inhibition may still be effective.
Risk Considerations and Clinical Implications
Risk considerations include the adequacy of warnings regarding avelumab and MCC. Since avelumab is approved specifically for MCC, the primary risk is not that the drug causes the disease, but that patients may experience disease progression despite treatment, or may develop immune-related adverse events. The prescribing information for avelumab includes warnings about immune-mediated adverse reactions, but the evidence does not suggest that avelumab causes MCC. For affected patients, causation-related considerations center on whether avelumab treatment contributed to disease progression or adverse outcomes. The timeline between exposure and documented harm is relevant: in the case of immune-related adverse events, such as sarcoidosis reactivation, the onset can occur during treatment, as reported in the case of hypercalcaemia (https://pubmed.ncbi.nlm.nih.gov/31543781/). For avelumab-refractory MCC, progression is documented during or after avelumab therapy, and the timeline varies among patients. In summary, the evidence supports that avelumab is an effective treatment for metastatic MCC, but approximately half of patients may not respond or may become refractory. Immune-related adverse events can occur, but they are manageable. There is no evidence that avelumab causes MCC; rather, it is a therapeutic agent for this disease. The risk narrative should emphasize that patients and clinicians should be aware of the potential for disease progression and immune-related adverse events, and that alternative treatments, such as ipilimumab plus nivolumab, are available for avelumab-refractory cases.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC. There is no evidence that avelumab causes MCC; rather, it is used to treat the disease.
What are the risks of avelumab treatment?
Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as hypercalcaemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). Additionally, about 50% of patients may experience disease progression despite treatment (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.